US PTAB Patent Cases
5,620 decisions indexed
Page 6 of 188 · 5,620 total
Amazon.com, Inc. et al. v.InterDigital VC Holdings, Inc. et al.
Amazon has filed an IPR petition challenging InterDigital’s ’876 patent covering large‑block intra‑prediction in video codecs. The petition asserts obviousness over Xiong, VCEG‑AJ21, and H.264, seeking cancellation of claims 1‑18.
Google LLC v.Gamba Group Holdings LLC
Google LLC filed an IPR petition against Gamba Group Holdings LLC’s 9,772,193 patent covering Bluetooth and GPS‑based parking‑location methods. The petition asserts anticipation by Baese and Phillips and obviousness with Phillips and Soliman, seeking cancellation of claims 12, 13, and 15‑18. The Board has not yet ruled on institution.
Microsoft Corporation v.Qomplx LLC
Microsoft has petitioned the PTAB to invalidate Qomplx’s multi-factor authentication patent, asserting that the claims are obvious over the Kirti patent and the Coffin textbook. The petition seeks institution of IPR on claims 1‑21, 23‑28, and 30.
Guardant Health, Inc. v.Tempus AI, Inc.
Guardant Health filed an IPR petition seeking cancellation of all 18 claims of Tempus AI’s 10,991,097 patent, asserting anticipation by Chukka and obviousness over Chukka combined with Jones, Sebastiao, and Gallas. The petition argues the prior art was not considered during prosecution.
Microsoft Corporation v.Qomplx LLC
Microsoft has filed a petition for inter partes review of Qomplx’s U.S. Patent 12,218,934 covering contextual, risk‑based multi‑factor authentication. The petition asserts that claims 1‑30 are obvious over prior art including the Kirti patent, the Coffin textbook, and Vemulapalli’s virtual‑machine teachings. No objective evidence of non‑obviousness is presented.
Microsoft Corporation v.Sandpiper CDN, LLC
Microsoft has filed an IPR petition challenging all 50 claims of Sandpiper CDN’s ’053 patent, asserting obviousness over a suite of CDN‑related prior art. The petition seeks institution of the proceeding and cancellation of the claims.
Microsoft Corporation v.Sandpiper CDN, LLC
Microsoft has filed an IPR petition challenging U.S. Patent 10,701,173, which covers CDN cache‑policy methods. The petition alleges obviousness over multiple prior‑art references and seeks cancellation of all fourteen claims.
Paragon 28, Inc. v.TREACE MEDICAL CONCEPTS, INC.
Treace Medical announced a confidential settlement with Fusion Orthopedics, ending a lawsuit over bunion‑correction patents. The settlement resolves claims of infringement, trademark, and copyright disputes.
Paragon 28, Inc. v.TREACE MEDICAL CONCEPTS, INC.
Paragon 28 seeks to invalidate Treace Medical Concepts' 12,268,428 bunion‑correction patent, alleging that all 30 claims are anticipated or obvious over well‑known surgical textbooks and prior‑art patents. The petition lists ten grounds covering §§102 and 103 and requests the Board to institute review and cancel the claims.
Pfizer Inc. v.Pogona, LLC
Pfizer has filed an IPR petition seeking cancellation of all 19 claims of U.S. Patent 11,058,757 covering pneumococcal conjugate vaccines, arguing that the claims are anticipated or obvious over prior art such as Alexander and Gu, plus extensive epidemiology literature.
Paragon 28, Inc. v.TREACE MEDICAL CONCEPTS, INC.
Treace Medical announced a confidential settlement with Fusion Orthopedics, ending a patent infringement lawsuit tied to its Lapiplasty bunion‑correction system. The settlement concludes the related PGR proceeding (PGR2026‑00017).
Paragon 28, Inc. v.TREACE MEDICAL CONCEPTS, INC.
Paragon 28 seeks to invalidate all 30 claims of Treace's bunion‑correction patent, alleging lack of written description, enablement, and obviousness over prior‑art guides and textbooks.
Nyxoah, Inc. et al. v.Inspire Medical Systems, Inc.
Nyxoah has filed an IPR petition seeking to invalidate Inspire Medical Systems' patent on hypoglossal nerve stimulation for sleep apnea. The petition asserts obviousness over prior‑art neurostimulator references (Durand/Hoegh and Headley/Tran). The Board is asked to institute review and cancel the claims.
Ebury Partners UK Ltd. v.--
Ebury Partners UK Ltd. and Intercurrency Software LLC entered into a settlement that grants Ebury a royalty‑free license to several patents covering cross‑border payments, includes covenants not to sue, and mandates dismissal of the pending IPR and related lawsuit.
Microsoft Corporation v.Sandpiper CDN, LLC
Microsoft seeks Director Review of a PTAB institution decision that ordered review of an expired content‑delivery patent owned by Sandpiper CDN. The petition argues the Board misapplied settled‑expectations doctrine and misread the district‑court record, making the decision an outlier.
Ebury Partners UK Ltd. v.--
Ebury Partners UK Ltd. moved to withdraw its IPR petition after settling with Intercurrency Software LLC. The Board was asked to terminate the proceeding, which was unopposed and at an early stage.
Microsoft Corporation v.Sandpiper CDN, LLC
The PTAB denied Google’s petitions for Director Review of institution decisions in four IPRs against Sandpiper CDN, keeping the institutions intact.
Microsoft Corporation v.Sandpiper CDN, LLC
Microsoft has filed an IPR petition challenging Sandpiper CDN’s 9,762,692 patent covering CDN popularity‑based routing and content partitioning, asserting obviousness over Seed and Swildens references.
Ebury Partners UK Ltd. v.--
Ebury Partners UK Ltd. petitions the PTAB to invalidate 16 claims of Intercurrency Software’s ‘701 patent, asserting that the claims are obvious over a combination of prior‑art trading systems (Calo, Rude, Sellberg, Szoc, Davidowitz).
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an IPR on Inari Medical’s 11,697,012 patent covering hemostasis valves for aspiration catheters after finding a reasonable likelihood that Imperative Care will prevail on at least one of the nine challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care challenged Inari Medical’s 11,844,921 B2 hemostasis valve patent. The PTAB found a reasonable likelihood of unpatentability and instituted inter partes review on all 18 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,554,005 B2 catheter aspiration patent after Imperative Care showed a reasonable likelihood of success on at least one claim. The review covers all 15 claims and four obviousness grounds involving Garrison, Schaffer, Hartley, and Eller references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,974,910 patent after finding Imperative Care likely to succeed on at least one claim, focusing on obviousness over Garrison, Laub, and Aklog references.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care successfully instituted an IPR against Inari Medical's 11,969,333 B2 patent covering intravascular clot removal. The Board found a reasonable likelihood of unpatentability based on obviousness over Laub, Garrison, and related references, and instituted review on all 36 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after Imperative Care showed a reasonable likelihood of success, focusing on the definition of “filament” and its flexibility versus prior art.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care has filed an IPR petition challenging Inari Medical’s U.S. Patent 12,156,669 covering an endovascular clot‑removal system. The petition asserts anticipation and obviousness over multiple prior‑art references, including Garrison, Goff, Brady, Pons, Schaffer, and Hartley. The Board must decide whether to institute the review.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully invalidated SitNet’s ’932 patent claims covering targeted advertising in situational networks. The Board found all challenged claims (12‑21) obvious over Amidon, Walsh, Shahine, and Jones. The decision clears Meta’s path for its ad‑tech offerings.
Meta Platforms, Inc. v.SitNet, LLC
Meta Platforms successfully challenged SitNet’s ’682 patent covering situational networks. The PTAB found all 20 claims unpatentable as obvious over prior art references Burfeind and Crowley. The patent owner did not respond, leaving the petitioner’s arguments unopposed.
Magnolia Medical Technologies, Inc. v.Kurin, Inc.
Magnolia Medical Technologies petitions the PTAB to invalidate claims 1‑24 of Kurin’s blood‑sample optimization device, asserting that the Bullington800 publication (alone and combined with Brancazio and Liu) anticipates or makes the claims obvious. The petition seeks institution and cancellation of all challenged claims.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.